2026 Leads Prescription 
World of DTC Marketing
FEBRUARY 22, 2021
billion by 2026. Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC.
PM360
SEPTEMBER 21, 2023
As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.
PM360
SEPTEMBER 21, 2023
As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Figure 1: Share of net spending for specialty and traditional prescription medications. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.
Clarivate
AUGUST 7, 2024
Express Scripts ClearNetwork (effective from early 2024) Cost-plus pricing model; includes ESI’s 65,000-plus site retail pharmacy network; prescription pricing is based on the lowest of three benchmarks: NADAC, WAC or PAC; Pharmacies receive a flat dispensing fee plus up to 15% markup.
Clarivate
SEPTEMBER 5, 2024
Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. With the passage of the Inflation Reduction Act (IRA), the United States government gained the ability to directly negotiate drug prices with manufacturers.
pharmaphorum
JANUARY 29, 2023
While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. Secondly, pressure on healthcare spending is leading to greater consolidation.
Expert insights. Personalized for you.
181 
Let's personalize your content